Phenotypic Drug Susceptibility Assay for Influenza Virus Neuraminidase Inhibitors

Clinical and Diagnostic Laboratory Immunology

Volumn 11, Issue 1, 2004, Pages 21-28

  McSharry, James J ^a   McDonough, Ann C ^a   Olson, Betty A ^a   Drusano, George L ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; OSELTAMIVIR; PERAMIVIR; RIBAVIRIN; SIALIDASE; SIALIDASE INHIBITOR; ZANAMIVIR;

ANIMAL CELL; ARTICLE; BIOASSAY; CONCENTRATION RESPONSE; DRUG RESISTANCE; DRUG SENSITIVITY; FLUORESCENCE ACTIVATED CELL SORTING; GENE MUTATION; IC 50; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INTERMETHOD COMPARISON; NEURAMINIDASE INHIBITION ASSAY; NONHUMAN; PHENOTYPE; PHENOTYPIC DRUG SUSCEPTIBILITY ASSAY; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS YIELD REDUCTION ASSAY;

ACETAMIDES; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DOGS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; FLOW CYTOMETRY; GUANIDINES; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; MICROBIAL SENSITIVITY TESTS; NEURAMINIDASE; OSELTAMIVIR; PHENOTYPE; PYRANS; SIALIC ACIDS; VIRUS REPLICATION; ZANAMIVIR;

EID: 0347758637     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.11.1.21-28.2004     Document Type: Article

References (61)

1. Babu, Y. S., P. Chand, S. Bantia, P. Kotian, A. Dehghani, Y. El-Kattan, T.-H. Lin, T. L. Hutchison, A. J. Elliott, C. D. Parker, S. L. Ananth, L. L. Horn, G. W. Laver, and J. A. Montgomery. 2000. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. 43:3482-3486.
2. Bantia, S., C. D. Parker, S. L. Ananth, L. L. Horn, K. Andries, P. Chand, P. L. Kotian, A. Dehghani, Y. El-Kattan, T. Lin, T. L. Hutchison, J. A. Montgomery, D. L. Kellog, and Y. S. Babu. 2001. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 45:1162-1167.
3. Barnett, J. M., A. Cadman, D. Gor, M. Dempsey, M. Walters, A. Candlin, M. Tisdale, P. J. Morley, I. J. Owens, R. J. Fenton, A. P. Lewis, E. C. J. Claas, G. F. Rimmelzwaan, R. DeGroot, and A. D. M. E. Osterhaus. 2000. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase 11 clinical efficacy studies. Antimicrob. Agents Chemother. 44:78-87.
4. Baum, E. Z., P. C. Wagaman, L. Ly, I. Turchi, J. Le, D. Bucher, and K. Bush. 2003. A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding. Antivir. Res. 59:13-22.
5. Boivin, G., and N. Goyette. 2002. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antivir. Res. 54:143-147.
6. Calfee, D. P., A. W. Peng, L. M. Cass, M. Lobo, and F. G. Hayden. 1999. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob. Agents Chemother. 43:1616-1620.
7. Carr, J., J. Ives, L. Kelly, R. Lambkin, J. Oxford, D. Mendel, L. Tai, and N. Roberts. 2002. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antivir. Res. 54:79-88.
8. Chutkowski, C., B. Olson, A. McDonough, J. Mahoney, and J. J. McSharry. 2002. Use of a single monoclonal antibody to determine the susceptibilities of herpes simplex virus type 1 and type 2 clinical isolates to acyclovir. Clin. Diagn. Lab. Immunol. 9:1379-1381.
9. Couch, R. B. 2000. Prevention and treatment of influenza. N. Engl. J. Med. 343:1778-1786.
10. Drusano, G. L., S. L. Preston, D. Smee, K. Bush, K. Bailey, and R. W. Sidwell. 2001. Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing. Antimicrob. Agents Chemother. 45:2115-2118.
11. Englund, J. A., R. E. Champlin, P. R. Wyde, H. Kantarjian, R. L. Atmar, J. Tarrand, H. Yousuff, H. Regnery, A. L. Klimov, N. J. Cox, and E. Whimbey. 1998. Common emergence of amantadine and rimantadine resistant influenza A viruses in symptomatic immunocompromised adults. Clin. Infect. Dis. 26:1418-1424.
12. Furuta, Y., K. Takahashi, Y. Fukuda, M. Kuno, T. Kamiyama, K. Kozaki, N. Nomura, H. Egawa, S. Minami, Y. Watanabe, H. Narita, and K. Shiraki. 2002. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 46:977-981.
13. Govorkova, E. A., I. A. Leneva, O. G. Goloubeva, K. Bush, and R. G. Webster. 2001. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Chemother. 45:2723-2732.
14. Gubareva, L. V., R. Bethell, G. J. Hart, K. G. Murti, C. R. Penn, and R. G. Webster. 1996. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-neu5ac2en. J. Virol. 70:1818-1827.
15. Gubareva, L. V., L. Kaiser, and F. G. Hayden. 2000. Influenza virus neuraminidase inhibitors. Lancet 355:827-835.
16. Gubareva, L. V., L. Kaiser, M. N. Matrosovich, Y. Soo-Hoo, and F. G. Hayden. 2001. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183:523-531.
17. Gubareva, L. V., M. N. Matrosovich, M. K. Brenner, R. C. Bethell, and R. G. Webster. 1998. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178:1257-1262.
18. Gubareva, L. V., R. G. Webster, and F. G. Hayden. 2001. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza viruses and neuraminidase inhibitor-resistant variants. Antimicrob. Agents Chemother. 45:3403-3408.
19. Gubareva, L. V., R. G. Webster, and F. G. Hayden. 2002. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antivir. Res. 53:47-61.
20. Hatta, H., P. Gao, P. Halfmann, and Y. Kawaoka. 2001. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 293:1840-1842.
21. Hayden, F. G., J. M. Cote, and R. G. Douglas. 1980. Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob. Agents Chemother. 17:865-870.
22. Hayden, F. G., and R. B. Couch. 1992. Clinical and epidemiological importance of influenza A viruses resistant to amantadine and rimantidine. Rev. Med. Virol. 2:89-96.
23. Hayden, F. G., L. V. Gubareva, A. S. Monto, T. C. Klein, M. J. Elliott, J. M. Hammond, S. J. Sharp, M. J. Ossi, et al. 2000. Inhaled zanamivir for the prevention of influenza in families. N. Engl. J. Med. 343:1282-1289.
24. Herlocher, M. L., J. Carr, J. Ives, S. Elias, R. Truscon, N. Roberts, and A. S. Monto. 2002. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antivir. Res. 54:99-111.
25. Ives, J. A. L., J. A. Carr, D. B. Mendel, C. Y. Tai, R. Lambkin, L. Kelly, J. S. Oxford, F. G. Hayden, and N. A. Roberts. 2002. The H274Y mutation in the influenza A/HIN1 neuraminidase active site following oseltamivir phosphate treatment leaves virus severely compromised both in vitro and in vivo. Antivir. Res. 55:307-317.
26. Kati, W. M., D. Montgomery, R. Carrick, L. Gubareva, C. Maring, K. McDaniel, K. Steffy, A. Molla, F. Hayden, D. Kempf, and W. Kohlbrenner. 2002. In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Antimicrob. Agents Chemother. 46:1014-1021.
27. Kati, W. M., D. Montgomery, C. Maring, V. S. Stoll, V. Giranda, X. Chen, W. G. Laver, W. Kohlbrenner, and D. W. Norbeck. 2001. Novel α- and β-amino acid inhibitors of influenza virus neuraminidase. Antimicrob. Agents Chemother. 45:2563-2570.
28. Krug, R. M. 2003. The potential use of influenza virus as an agent for bioterrorism. Antivir. Res. 57:147-150.
29. Leneva, I. A., O. Goloubeva, R. J. Fenton, M. Tisdale, and R. G. Webster. 2001. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob. Agents Chemother. 45:1216-1224.
30. Leneva, I. A., N. Roberts, E. A. Govorkova, O. G. Goloubeva, and R. G. Webster. 2000. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/1074/99 (H9N2) influenza viruses, Antivir. Res. 48:101-115.
31. Li, W., P. A. Escarbe, E. J. Eosenberg, L. C. Cundy, C. Sweet, K. J. Jakeman, J. Merson, W. Lew, M. Williams, L. Zhang, C. U. Kim, N. Bischofberger, M. S. Chen, and D. B. Mendel. 1988. Identification of GS4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS4071. Antimicrob. Agents Chemother. 42:647-653.
32. McKimm-Breschkin, J. L. 2000. Resistance of influenza viruses to neuraminidase inhibitors-a review. Antivir. Res. 47:1-17.
33. McKimm-Breschkin, J., T. Trivedi, A. Hampson, A. Hay, A. Kilmov, M. Tashiro, F. Hayden, and M. Zambon. 2003. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47:2264-2272.
34. MeSharry, J. J. 1999. Antiviral drug susceptibility assays: going with the flow. Antivir. Res. 43:1-21.
35. MeSharry, J. J., N. S. Lurain, G. L. Drusano, A. L. Landay, M. Notka, M. R. G. O'Gorman, A. Weinberg, H. M. Shapiro, P. S. Reichelderfer, and C. Crumpacker. 1998. Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolates. Antimicrob. Agents Chemother. 42:2326-2331.
36. MeSharry, J. J., A. McDonough, B. Olson, S. Hallenberger, J. Reefschlaeger, W. Bender, and G. L. Drusano. 2001. Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir. Antimicrob. Agents Chemother. 45:2925-2927.
37. McSharry, J. J., A. McDonough, B. Olson, C. Talarico, M. Davis, and K. K. Biron. 2001. Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94. Clin. Diagn. Lab. Immunol. 8:1279-1281.
38. Molla, A., W. Kati, R. Carrick, K. Steffy, Y. Shi, D. Montgomery, N. Gusick, V. S. Stoll, K. D. Stewart, T. I. Ng, C. Maring, D. J. Kempf, and W. Kohlbrenner. 2002. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. J. Virol. 76:5380-5386.
39. Munoz, F. M., G. J. Galasso, J. M. Gwaltney, Jr., F. G. Hayden, B. Murphy, R. Webster, P. Wright, and R. B. Couch. 2000. Current research on influenza and other respiratory viruses. Second international symposium. Antivir. Res. 46:91-124.
40. Nobusawa, E., H. Ishihara, T. Morishita, K. Sato, and K. Nakajima. 2000. Change in receptor-binding specificity of recent human influenza A viruses (H3N2): a single amino acid change in hemagglutinin altered its recognition of sialyloligosaccharides. Virology 278:587-598.
41. O'Keefe, B. R., D. F. Smee, J. A. Turpin, C. J. Saucedo, K. R. Gustafson, T. Mori, D. Blakeslee, B. Buekheit, and M. R. Boyd. 2003. Potent anti anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob. Agents Chemother. 47:2518-2525.
42. Potier, M., L. Mameli, M. Belisle, L. Dallaire, and S. B. Melancon. 1979. Fluorometric assay of neuraminidase with sodium (4-methylumbelliferyl-α -D-N-acetylneuramininate) substrate. Anal. Biochem. 94:287-296.
43. Schmidt, A. C., R. B. Couch, G. J. Galasso, F. G. Hayden, J. Mills, B. R. Murphy, and R. M. Chanock. 2001. Current research on respiratory viral infections. Third international symposium. Antivir. Res. 50:157-196.
44. Seo, S. H., E. Hoffmann, and R. G. Webster. 2002. Lethal H5N1 influenza viruses escape host antiviral cytokine responses. Nat. Med. 8:950-954.
45. Sidwell, R. W., and D. F. Smee. 2000. In vitro and in vivo assay systems for study of influenza virus inhibitors. Antivir. Res. 48:1-16.
46. Sidwell, R. W., D. F. Smee, J. H. Huffman, D. L. Barnard, K. W. Bailey, J. D. Morrey and Y. S. Babu. 2001. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RWJ-270201. Antimicrob. Agents Chemother. 45:749-757.
47. Sidwell, R. W., D. F. Smee, J. H. Huffman, D. L. Barnard, J. D. Morrey, K. Bailey, W. Feng, Y. S. Babu, and K. Bush. 2001. Influence of virus strain, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201. Antivir. Res. 51:179-187.
48. Smee, D. F., J. H. Huffman, A. C. Morrison, D. L. Barnard, and R. W. Sidwell. 2001. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob. Agents Chemother. 45:743-748.
49. Smee, D. F., R. W. Sidwell, A. C. Morrison, K. W. Bailey, E. Z. Baum, L. Ly, and P. C. Wagaman. 2001. Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201. Antivir. Res. 52:251-259.
50. Subbarao, K., A. Klimov, J. Katz, H. Regnery, W. Lim, H. Hall, M. Perdue, D. Swayne, C. Bender, J. Huang, M. Hemphill, T. Rowe, M. Shaw, X. Xu, K. Fukuda, and N. Cox. 1998. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279:393-396.
51. Sweet, C., K. J. Jakeman, K. Bush, P. C. Wagaman, L. A. McKown, A. J. Streeter, D. Desai-Krieger, P. Chand, and Y. S. Babu. 2002. Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection. Antimicrob. Agents Chemother. 46:996-1004.
52. Tisdale, M. 2000. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev. Med. Virol. 10:45-55.
53. Treanor, J. J., F. G. Hayden, P. S. Vrooman, R. Barbarash, R. Bettis, D. Riff, S. Singh, N. Kinnersley, P. Ward, R. G. Mills et al. 2000. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. A randomized controlled trial. JAMA 283:1016-1024.
54. Wagaman, P. C., M. A. Leong, and K. A. Simmen. 2002. Development of a novel influenza A antiviral assay. J. Virol. Methods 105:105-114.
55. Wang, M. Z., C. Y. Tai, and D. B. Mendel. 2002. Mechanism by which mutations at His274 alter sensitivity of influenza A virus N1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob. Agents Chemother. 46:3809-3816.
56. Webster, R. G., Y. Guan, M. Peiris, D. Walker, S. Krauss, N. N. Zhou, E. Govorkova, T. M. Ellis, K. C. Dyrting, T. Sit, D. R. Perez, and K. K. Shortridge. 2002. Characterization of H5N1 influenza viruses that continue to circulate in geese in southeastern China. J. Virol. 76:118-126.
57. Wetherall, N. T., T. Trivedi, J. Zeller, C. Hodges-Savola, J. L. McKimm-Breschkin, M. Zambon, and F. G. Hayden. 2003. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the Neuraminidase Inhibitor Susceptibility Network. J. Clin. Microbiol. 41:742-750.
58. Whitley, R. J., F. G. Hayden, K. S. Reisinger, N. Young, K. R. Dutkowski, D. Ipe, R. G. Mills, and P. Ward. 2002. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20:127-133.
59. Woods, J. M., R. C. Betbell, J. A. Coates, N. Healy, S. A. Hiscox, B. A. Pearson, D. M. Ryan, J. Ticedburst, J. Tilling, S. M. Walcott, and C. R. Penn. 1993. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob. Agents Chemother. 37:1473-1479.
60. Yuen, K. Y., P. K. S. Chen, M. Peiris, D. N. C. Tsang, T. L. Que, K. F. Shortridge, P. T. Cheung, W. K. To, E. T. F. Ho, R. Sung, A. F. B. Cheng, et al. 1998. Clinical features and rapid viral diagnosis of human disease associated with avian influenza H5N1 virus. Lancet 351:467-471.
61. Zambon, M., and F. G. Hayden. 2001. Position statement: global neuraminidase inhibitor susceptibility network. Antivir. Res. 49:147-156.